Immunosuppressed prostate cancer patients treated by brachytherapy seem to enjoy similar cancer control rates as the similarly treated nonimmunosuppressed population. It is recognized, however, that a much larger cohort of immunosuppressed patients would need to be studied to demonstrate statistical equivalence.

Symptoms following brachytherapy each have their own temporal pattern for development and resolution. These patterns are well explained by the underlying pathophysiology of therapeutic radiation injury and healing. Men and their partners can use this information to guide and inform treatment decisions.

No abstract

No abstract

openAccessArticle: FalsePage Range: vii-viidoi: 10.1016/B978-1-4377-1637-5.00094-8Harvest Date: 2016-01-12 15:15:33issueName:cover date: 2012-01-01pubType